Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11885389 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL3072771 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL16438222 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL6555701 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL4863760 | 1.00 | — | — | |
| SCHEMBL317775 | 0.90 | — | — | |
| SCHEMBL30130365 | 0.88 | CA2 (0.34) | CA2ADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL1781746 | 0.87 | — | — | |
| SCHEMBL28880086 | 0.85 | CA2 (0.34) | CA2 | |
| SCHEMBL23647292 | 0.83 | CA2 (0.44) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240590-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9492555-B2 | Nucleophilic catalysts for oxime linkage | BAXALTA INCORPORATED (US) | 2016-11-15 | — | — | US | disclosed |
| US-8945897-B2 | Materials and methods for conjugating a water soluble fatty acid derivative to a protein | BAXTER INTERNATIONAL INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140121351-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8642737-B2 | Nucleophilic catalysts for oxime linkage | BAXTER INTERNATIONAL INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130310546-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME | BAXALTA INCORPORATED | 2013-11-21 | — | — | US | disclosed |
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | BAXTER HEALTHCARE S.A. (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120035344-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE S.A. (CH) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240590-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | CA2 509/4885ADRB2 4683/4885ADRB1 4649/4885 |
| US-20120190096-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | FABP1, FABP4, FABP5 | CA2 3844/4885ADRB2 4713/4885ADRB1 4693/4885 |
| US-20120035344-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | CA2 509/4885ADRB2 4683/4885ADRB1 4649/4885 |
| US-20130310546-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME | OGA, LPO, CA12 | CA2 178/4885ADRB2 4412/4885ADRB1 4653/4885 |
| US-20140121351-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | CA2 509/4885ADRB2 4683/4885ADRB1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.